These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 1317371

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. In vitro activity of lomefloxacin against multiply resistant Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus epidermidis.
    DiVincenzo CA, Shatzer KL, Venezio FR.
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):13S-16S. PubMed ID: 2507220
    [Abstract] [Full Text] [Related]

  • 26. In vitro postantibiotic effect of imipenem and enoxacin alone and in combination against Pseudomonas aeruginosa.
    Hostacká A.
    Pharmazie; 1997 Jul; 52(7):544-6. PubMed ID: 9266592
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Surveillance of multi-drug resistant Pseudomonas aeruginosa in an urban tertiary-care teaching hospital.
    Jung R, Fish DN, Obritsch MD, MacLaren R.
    J Hosp Infect; 2004 Jun; 57(2):105-11. PubMed ID: 15183239
    [Abstract] [Full Text] [Related]

  • 29. In vitro activity of aryl fluoroquinolones, Abbott 56619 and Abbott 56620, compared to ciprofloxacin, norfloxacin and beta-lactams versus multidrug-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Meyer RD, Liu S.
    Chemotherapy; 1986 Jun; 32(5):425-30. PubMed ID: 3093154
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.
    Kitamura A, Hoshino K, Kimura Y, Hayakawa I, Sato K.
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1467-71. PubMed ID: 7492087
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Synergistic activity of the novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species.
    Fung-Tomc JC, Gradelski E, Valera L, Huczko E, Bonner DP.
    Int J Antimicrob Agents; 2002 Jul; 20(1):57-60. PubMed ID: 12127712
    [Abstract] [Full Text] [Related]

  • 37. In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy.
    Le Thomas I, Couetdic G, Clermont O, Brahimi N, Plésiat P, Bingen E.
    J Antimicrob Chemother; 2001 Oct; 48(4):553-5. PubMed ID: 11581237
    [Abstract] [Full Text] [Related]

  • 38. Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.
    Lafredo SC, Foleno BD, Fu KP.
    Chemotherapy; 1993 Oct; 39(1):36-9. PubMed ID: 8383031
    [Abstract] [Full Text] [Related]

  • 39. [Development of multi-drug resistant mutants of clinical isolates of Pseudomonas aeruginosa after exposure to fluoroquinolone].
    Hasegawa M, Kobayashi I, Saika T, Shimadzu M, Nishida M.
    Kansenshogaku Zasshi; 1996 Feb; 70(2):123-31. PubMed ID: 8851384
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.